Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05)

An open label feasibility study using BPX-04 topical minocycline gel in papulopustular rosacea.

Study Overview

• Status: Completed
• Conditions: Moderate to Severe Papulopustular Rosacea
• Intervention / Treatment: Drug: BPX-04 1% minocycline topical gel; Drug: BPX-04 2% minocycline topical gel; Drug: BPX-04 vehicle topical gel

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • San Diego, California, United States, 92123
      • Study Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or female subjects ≥18 years of age at the time of consent.
2. Subjects do not have any medical conditions, other than rosacea, that in the opinion of the investigator, put the subject at unacceptable risk or could interfere with study assessments or integrity of the data.
3. A clinical diagnosis of moderate to severe (Grade 3 or 4) facial rosacea (papulopustular (Subtype 2) or mixed erythematotelangiectatic (Subtype 1) and papulopustular (Subtype 2)) as determined by the Investigator's Global Assessment (IGA) at Visit 1/Screening.

4. Female subjects of childbearing potential (including pre-puberty) are willing to use effective contraceptive method for at least 28 days before baseline (Day 0) and at least 28 days after the last study product administration or have a sterilized or same-sex partner for the duration of the study. Hormonal contraceptives must be on a stable dose for at least 12 weeks before baseline (Day 0). Subjects using low dose oral contraceptives must use a second form of birth control (e.g., barrier method such as condoms with spermicide).

   Note: Female subjects of non-childbearing potential are defined as follows:

   1. Female subjects who have had surgical sterilization (hysterectomy, bilateral oophorectomy, bilateral salpingectomy, or bilateral tubal ligation);
   2. Female subjects who have had a cessation of menses for at least 12 months and a follicle-stimulating hormone (FSH) test confirming non-childbearing potential (refer to the central laboratory reference range for menopausal women) or cessation of menses for at least 24 months without FSH levels confirmed;
5. Female subjects of childbearing potential must have a negative urine pregnancy test at screening and baseline (Day 0).
6. Treatment with hormonal therapy must be on a stable dose and frequency for at least 12 weeks before baseline (Day 0) and must remain stable throughout the study.
7. Subjects who use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens must have used the same product brands/types for a minimum period of 14 days prior to baseline (Day 0), must agree not to change brand/type or frequency of use throughout the study and must agree not to use make-up, facial moisturizers, creams, lotions, cleansers and/or sunscreens on the clinic visit days before the visit.
8. Subjects must be capable of giving informed consent and the written informed consent must be obtained prior to any study-related procedures.

Exclusion Criteria:

1. Have a history of skin disease, presence of skin condition or excessive facial hair the PI believes would interfere with the study
2. Have moderate or severe rhinophyma, severe telangiectasia or plaque-like facial edema
3. Have rosacea conglobata or fulminans, corticosteroid induced rosacea or facial erythrosis other than rosacea
4. Have ocular rosacea of a severity that requires systemic treatment
5. Have a history of any adverse reaction to minocycline or other tetracycline class antibiotic
6. Have a clinically significant chemistry or hematology value at baseline or have an ALT or AST at screening that is greater than or equal to 2x normal
7. Have conditions or factors that the PI believes may affect the response of the skin or the interpretation of the results
8. Participated in any clinical study with exposure to any investigational treatment or product within the previous 30 days, or plan on concurrent participation in other studies
9. Have used on the face an OTC topical medication for the treatment of rosacea within 4 weeks prior to baseline.
10. Have used prescription topical (on the face) or oral antibiotics or corticosteroids within 4 weeks prior to baseline.
11. Have had a facial procedure such as chemical peel, laser, microdermabrasion within 8 weeks prior to baseline
12. Have received photodynamic therapy or phototherapy with blue or red light within 12 weeks prior to baseline
13. Have used an oral retinoid within 6 months or a topical retinoid within 3 months prior to baseline
14. Current drug or alcohol abuse
15. Female subject who is breastfeeding, pregnant or who is planning a pregnancy during the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: BPX-04 1% Minocycline Topical Gel; once daily topical administration of 1% minocycline gel to the face	Drug: BPX-04 1% minocycline topical gel; once daily administration of topical minocycline gel to face
Experimental: BPX-04 2% Minocycline Topical Gel; once daily topical administration of 2% minocycline gel to the face	Drug: BPX-04 2% minocycline topical gel; once daily administration of topical minocycline gel to face
Placebo Comparator: BPX-01 Vehicle Topical Gel; once daily topical administration of vehicle gel to the face	Drug: BPX-04 vehicle topical gel; once daily administration of topical minocycline gel to face

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator's Global Assessment	papules, pustules and erythema	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lesion count	papules and pustules	12 weeks

Collaborators and Investigators

• Sponsor: BioPharmX, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 29, 2017
• Primary Completion (Actual): June 19, 2018
• Study Completion (Actual): June 19, 2018

Study Registration Dates

• First Submitted: February 8, 2017
• First Submitted That Met QC Criteria: February 8, 2017
• First Posted (Actual): February 10, 2017

Study Record Updates

• Last Update Posted (Actual): January 31, 2019
• Last Update Submitted That Met QC Criteria: January 29, 2019
• Last Verified: January 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Rosacea; Anti-Infective Agents; Anti-Bacterial Agents; Minocycline
• Other Study ID Numbers: BPX-01-C05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No